Related references
Note: Only part of the references are listed.Molecular Dynamics Validation of Crizotinib Resistance to ALK Mutations (L1196M and G1269A) and Identification of Specific Inhibitors
Nagasundaram Nagarajan et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2017)
Non-Small Cell Lung Cancer, Version 5.2017 Clinical Practice Guidelines in Oncology
David S. Ettinger et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2017)
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F
Alice T. Shaw et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking
Fu Chen et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2016)
Insight on Mutation-Induced Resistance from Molecular Dynamics Simulations of the Native and Mutated CSF-1R and KIT
Priscila Da Silva Figueiredo Celestino Gomes et al.
PLOS ONE (2016)
Biological activities of imidazo[2,1-b][1,3,4]-thiadiazole derivatives: A review
Bhoomendra A. Bhongade et al.
JOURNAL OF SAUDI CHEMICAL SOCIETY (2016)
ff14SB: Improving the Accuracy of Protein Side Chain and Backbone Parameters from ff99SB
James A. Maier et al.
JOURNAL OF CHEMICAL THEORY AND COMPUTATION (2015)
Computationally unraveling how ceritinib overcomes drug-resistance mutations in ALK-rearranged lung cancer
Zhong Ni et al.
JOURNAL OF MOLECULAR MODELING (2015)
I1171 missense mutation (particularly I1171N) is a common resistance mutation in ALK-positive NSCLC patients who have progressive disease while on alectinib and is sensitive to ceritinib
Sai-Hong Ignatius Ou et al.
LUNG CANCER (2015)
Clinical challenges in targeting anaplastic lymphoma kinase in advanced non-small cell lung cancer
Namrata Vijayvergia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance
Tatsushi Kodama et al.
CANCER LETTERS (2014)
Two Novel ALK Mutations Mediate Acquired Resistance to the Next-Generation ALK Inhibitor Alectinib
Ryohei Katayama et al.
CLINICAL CANCER RESEARCH (2014)
Updated Data of a Phase 1/2 Study (AF-001JP) of Alectinib, a CNS-Penetrant, Highly Selective ALK Inhibitor in ALK-rearranged Advanced NSCLC
T. Tamura et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2014)
Prospects on Strategies for Therapeutically Targeting Oncogenic Regulatory Factors by Small-Molecule Agents
Chih-Chien Chou et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2014)
Overcoming Drug Resistance in ALK- Rearranged Lung Cancer
Roman K. Thomas
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Assessing the performance of MM/PBSA and MM/GBSA methods. 5. Improved docking performance using high solute dielectric constant MM/GBSA and MM/PBSA rescoring
Huiyong Sun et al.
PHYSICAL CHEMISTRY CHEMICAL PHYSICS (2014)
CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study
Takashi Seto et al.
LANCET ONCOLOGY (2013)
A Pareto-Optimal Refinement Method for Protein Design Scaffolds
Lucas Gregorio Nivon et al.
PLOS ONE (2013)
High-Resolution Comparative Modeling with RosettaCM
Yifan Song et al.
STRUCTURE (2013)
Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802)
Kazutomo Kinoshita et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2012)
Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer
Robert C. Doebele et al.
CLINICAL CANCER RESEARCH (2012)
ALK Gene Amplified in Most Inflammatory Breast Cancers
Rabiya S. Tuma
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2012)
Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
D. Ross Camidge et al.
LANCET ONCOLOGY (2012)
CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant
Hiroshi Sakamoto et al.
CANCER CELL (2011)
Insights into ALK-Driven Cancers Revealed through Development of Novel ALK Tyrosine Kinase Inhibitors
Christine M. Lovly et al.
CANCER RESEARCH (2011)
Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)
J. Jean Cui et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
9-Substituted 6,6-Dimethyl-11-oxo-6,11-dihydro-5H-benzo[b]carbazoles as Highly Selective and Potent Anaplastic Lymphoma Kinase Inhibitors
Kazutomo Kinoshita et al.
JOURNAL OF MEDICINAL CHEMISTRY (2011)
Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK
Ryohei Katayama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain
Christian C. Lee et al.
BIOCHEMICAL JOURNAL (2010)
Cell Signaling by Receptor Tyrosine Kinases
Mark A. Lemmon et al.
CELL (2010)
Drug-target residence time: critical information for lead optimization
Hao Lu et al.
CURRENT OPINION IN CHEMICAL BIOLOGY (2010)
Residence time of receptor-ligand complexes and its effect on biological function
Peter J. Tummino et al.
BIOCHEMISTRY (2008)
Identification of ALK as a major familial neuroblastoma predisposition gene
Yael P. Mosse et al.
NATURE (2008)
Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma
Isabelle Janoueix-Lerosey et al.
NATURE (2008)
Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
Manabu Soda et al.
NATURE (2007)
Molecular recognition of protein kinase binding pockets for design of potent and selective kinase inhibitors
Jeffrey Jie-Lou Liao
JOURNAL OF MEDICINAL CHEMISTRY (2007)
Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK
Anna V. Galkin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Development and testing of a general amber force field (vol 25, pg 1157, 2004)
JM Wang et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2005)
UCSF chimera - A visualization system for exploratory research and analysis
EF Pettersen et al.
JOURNAL OF COMPUTATIONAL CHEMISTRY (2004)
Expression and functional analysis of the anaplastic lymphoma kinase (ALK) gene in tumor cell lines
WG Dirks et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Calculating structures and free energies of complex molecules: Combining molecular mechanics and continuum models
PA Kollman et al.
ACCOUNTS OF CHEMICAL RESEARCH (2000)
Share Paper
